Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)—protocol of randomised controlled trial AZIQUINE-ICU

BACKGROUND: Novel coronavirus SARS-CoV-2 is known to be susceptible in vitro to exposure to hydroxychloroquine and its effect has been found to be potentiated by azithromycin. We hypothesise that early administration of hydroxychloroquine alone or in combination with azithromycin can prevent respira...

Descripción completa

Detalles Bibliográficos
Autores principales: Duška, František, Waldauf, Petr, Halačová, Milada, Zvoníček, Václav, Bala, Jakub, Balík, Martin, Beneš, Jan, Klementová, Olga, Kozáková, Irena, Kubricht, Viktor, Le Roy, Anne, Vymazal, Tomáš, Řehořová, Veronika, Černý, Vladimír
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341702/
https://www.ncbi.nlm.nih.gov/pubmed/32641163
http://dx.doi.org/10.1186/s13063-020-04566-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341702/
https://www.ncbi.nlm.nih.gov/pubmed/32641163
http://dx.doi.org/10.1186/s13063-020-04566-x

Ejemplares similares